
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0301 | 0.0301 | 0.0301 | 0 | 0 | CS |
4 | 0 | 0 | 0.0301 | 0.0301 | 0.0301 | 0 | 0 | CS |
12 | -0.1889 | -86.2557077626 | 0.219 | 0.257406 | 0.0301 | 1231415 | 0.15517211 | CS |
26 | -0.2282 | -88.3468834688 | 0.2583 | 0.2972 | 0.0301 | 1651857 | 0.18030122 | CS |
52 | -0.9133 | -96.8094127623 | 0.9434 | 1.31 | 0.0301 | 989025 | 0.22621714 | CS |
156 | -2.4499 | -98.7862903226 | 2.48 | 5.75 | 0.0301 | 434321 | 0.71794136 | CS |
260 | -16.7299 | -99.8204057279 | 16.76 | 18.24 | 0.0301 | 394430 | 2.0569835 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions